Synergistic cytotoxicity of the CDK4 inhibitor Fascaplysin in combination with EGFR inhibitor Afatinib against Non-small Cell Lung Cancer

In the absence of suitable molecular markers, non-small cell lung cancer (NSCLC) patients have to be treated with chemotherapy with poor results at advanced stages. Therefore, the activity of the anticancer marine drug fascaplysin was tested against primary NSCLC cell lines established from pleural...

Descripción completa

Detalles Bibliográficos
Autores principales: Plangger, Adelina, Rath, Barbara, Hochmair, Maximilian, Funovics, Martin, Neumayer, Christoph, Zeillinger, Robert, Hamilton, Gerhard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Preclinical Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8993745/
https://www.ncbi.nlm.nih.gov/pubmed/34596822
http://dx.doi.org/10.1007/s10637-021-01181-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8993745/
https://www.ncbi.nlm.nih.gov/pubmed/34596822
http://dx.doi.org/10.1007/s10637-021-01181-8

Ejemplares similares